The JPM 2027 Playbook for Private Healthcare Services and Technology Companies: The Busiest Week of the Year, and How to Make It Count 

11 Views
The JPM 2027 Playbook for Private Healthcare Services and Technology Companies: The Busiest Week of the Year, and How to Make It Count 

The 45th Annual J.P. Morgan Healthcare Conference is approaching, which means JPM week is almost here. The week is a whirlwind: meetings are speed-dating sessions where participants run late, schedules change on the fly, it’ll inevitably be raining, and a 30-minute meeting slot can shrink to 15 before you’ve even sat down. But amid the chaos, JPM offers an important opportunity. Whether your IPO is 12 months or more than two years away, the companies that stand out start thinking like a public company long before they go public and leverage their time in San Francisco to build credibility with Wall Street.

Heading into my 16th JPM, I still haven’t figured out the right outerwear for mid-January in San Francisco, but I can say with confidence what distinguishes a successful week.

Where the Market Stands Heading Into 2027

For companies eyeing a 2027 or 2028 IPO, the bar is high, and the companies that clear it can show a track record that matches their story. The public markets have been quiet, with no new digital health listings since HeartFlow in August 2025 and only a handful of healthcare services IPOs since then. Investors continue to favor scaled businesses with strong unit economics and a clear path to profitability. While capital is available for the right stories, it is concentrated and investors are highly selective: according to Rock Health, U.S. digital health startups raised $3.7 billion across 114 deals in Q3, bringing the 2026 year-to-date total to $11.1 billion. But exits are increasingly coming through M&A rather than the public markets, with 45 digital health deals in Q3 and 164 year-to-date.

Meanwhile, the broader IPO tape has turned out to be choppier. Oura postponed its IPO in September, citing market uncertainty despite what it called strong demand, and issuers in other sectors also postponed or withdrew. The Fed raised rates in September, and the market is pricing at least one more increase by year-end.

Beyond this year’s macro environment, investors tend to run out of steam late in the year. By December, many are less interested in new risks or new ideas, but JPM resets that. It has the feel of a new school year: fresh budgets, fresh theses, and investors who are actively looking for the companies they will track through 2027. Wherever you are in your IPO planning, JPM is a great setting to begin unofficially testing the waters.

Learning from the Past: Peer Benchmarking for JPM

Many of the 2020 and 2021 IPOs leaned on big growth narratives, massive Total Addressable Markets (TAMs), and promises of profitability at some distant point in the future. They then struggled once they were public. The 2024 and 2025 healthcare services & technology class learned from that cycle. Hinge Health told a defensible story about its longer-term strategy, let the market know what to expect, kept news flowing, and delivered on its promises. Omada laid out a path to profitability at its IPO and then delivered it: adjusted EBITDA swung from a $29.4 million loss in 2024 to a $6.5 million profit in 2025 and reached $11 million in the second quarter of 2026.

The next IPO class will need to build on that foundation by raising its own level of rigor and acting like a public company earlier. These actions help give investors confidence that you are ready for the added scrutiny of the public markets, can establish a consistent beat-and-raise cadence, and will be a solid investment.

We hear investors and analysts often talk about companies and management teams as being “great public company” candidates. What does that take? Start building these habits now, and use your JPM meetings to practice them:

  • Message consistency: The CEO, CFO, and other key leaders tell a consistent story in every meeting.
  • Clear KPIs and milestones: The best companies make it easy for investors to track progress and know exactly what comes next.
  • Calibrated disclosure: They share enough depth to be credible, with a clear view of what they will and won’t say, ahead of the scrutiny public disclosure brings.
  • Realistic valuation framing: Public investors will anchor on where listed healthcare peers trade relative to their growth and margins, not on your last private round. They reward companies that can explain their valuation, not just assert it.

Shifting Your Storytelling Mindset

Part of acting like a public company is changing how you tell your story. Private companies raising earlier rounds of capital have learned to tell a big-picture, big-dream story. It works with those investors who are underwriting a vision. Public-market investors want a clear, specific, defensible story about the next 12 to 24 months and a proven track record.

Now is the time to rebuild your investor presentation with that in mind. Strategy comes before slides, so here are steps you must factor in:

  • Tighten the core. If you can’t explain the opportunity, the differentiation, and the “why now” in a few sentences, a longer deck won’t fix it. For example, we worked with a company years ago that had eight different potential growth avenues. Investors couldn’t tell where to focus their attention or which would genuinely move the needle, so we helped them narrow that to four core opportunities and share measurable updates quarterly, which resonated much more with investors.
  • Clarify the market opportunity. Be specific about the market you can credibly address, because the market won’t reward you for an unbelievably large number.
  • Simplify your growth story. Investors have plenty of investment opportunities to choose from, and a complicated or muddled growth algorithm will cause them to turn their attention to the next opportunity.
  • Let the proof points do the heavy lifting. Don’t just tell investors what makes you special; show them a specific example of it in action. Lead with hard ROI, customer outcomes, and case studies, so the facts make the argument for you.
  • Stay disciplined in forward-looking statements. This is the biggest mindset shift. You are on a public stage now, and people will remember what you said. Lofty projections can come back to haunt you, so a smaller commitment you can achieve builds more credibility than a bigger one you miss.

What Investors Will Actually Ask

Public-market investors need to check their diligence boxes, and it’s important to proactively offer the information they need, while also being prepared to address likely questions with succinct, consistent answers. Even if your company is unique in many ways, it’s human nature to compare something new to what we’re already familiar with, so be prepared to explain how you fit into the broader landscape and what differentiates you.  Investors are also working to determine your valuation, so give them the information they need to make an informed assessment.

Rehearse questions with people who have sat across from public-market investors and know what they say once the meeting ends. That feedback helps identify the gaps in your answers and ensure you are not surprised by anything in your JPM meetings. Some common questions below:

  1. “Why are you meeting with public-market investors now?” Have a clear answer that ties together customer demand, capital needs, and timing, including any intention to raise capital and what must be true first.
  1. “How do you compare to XYZ company that went public before you?” Expect to be measured on growth, margins, and efficiency against the recent IPO class, so know where you stand before they ask.
  1. “How should I think about your scale and profitability?” Show how you have scaled and how profitable you have been, using prior periods only, and let the track record carry the story, keeping comments on future trajectory general.
  1. “Who do you compete with?” Saying you don’t have any competition is a shot to your credibility. Investors will be hard pressed to believe that there is a multi-billion-dollar market that has zero competition. You may not have any direct competitors across all of your niche markets, so a stronger answer addresses competition by segment and the synergies of offering your solutions together.
  1. “How exposed is your business to changes in reimbursement, regulation, or policy?” Investors in this space will probe payer mix, customer concentration, and policy sensitivity, so have the numbers ready and a clear view of how you would respond.
  1. “What keeps you up at night?” While this might feel like a cop-out question, smart management teams will use it as an opportunity to further differentiate from peers, provide confidence that they have a firm understanding of their business, and hit on any final points to drive home before the meeting ends.

Make the Week Count

For private companies, JPM isn’t just another banking conference to attend; it’s a chance to raise your visibility and establish your credibility, laying the groundwork for the year ahead. The companies that do it well start early, pressure-test their story with people who will push back and arrive in January with a plan.

At ICR Healthcare, we act as a strategy-first sounding board. We open doors to the investors and industry thought leaders who shape how the market sees a company, so you become one worth watching. We give candid feedback on how your story lands, what public-market investors will expect, and how to act like a public company long before you file.

Want to pressure-test your story before JPM or talk through IPO readiness? Reach out to us at [email protected].

Back to news page

Disclaimer: This story is auto-aggregated by a computer program and has not been created or edited by Life Care Finance Guide.
Publisher: Source link

Leave a comment